Inventories

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Raw materials	$	—	$	911
Work in process		—		70
Finished goods		—		5
Total inventories	$	—	$	986

Due to the RIF and the Company’s decision to discontinue enrollment of patients in its clinical trial, the Company suspended manufacturing activities in June 2022 and disposed of substantially all inventories in July 2022, resulting in a write-down of $1.0 million in its inventories to net realizable value. Such expense is included in restructuring and impairment charges in the condensed statements of operations for the nine months ended September 30, 2022. See Note 13. Restructuring and Impairment Charges.